• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

针对冠状病毒的抑制剂的最新发现和开发。

Recent discovery and development of inhibitors targeting coronaviruses.

机构信息

PharmaCenter Bonn, Pharmaceutical Institute, Department of Pharmaceutical and Medicinal Chemistry, University of Bonn, An der Immenburg 4, D-53121 Bonn, Germany.

Department of Chemistry, Sri Krishna College of Engineering and Technology, Coimbatore, Tamil Nadu, India.

出版信息

Drug Discov Today. 2020 Apr;25(4):668-688. doi: 10.1016/j.drudis.2020.01.015. Epub 2020 Jan 30.

DOI:10.1016/j.drudis.2020.01.015
PMID:32006468
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7102522/
Abstract

Human coronaviruses (CoVs) are enveloped viruses with a positive-sense single-stranded RNA genome. Currently, six human CoVs have been reported including human coronavirus 229E (HCoV-229E), OC43 (HCoV-OC43), NL63 (HCoV-NL63), HKU1 (HCoV-HKU1), severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV), and MiddleEast respiratory syndrome (MERS) coronavirus (MERS-CoV). They cause moderate to severe respiratory and intestinal infections in humans. In this review, we focus on recent advances in the research and development of small-molecule anti-human coronavirus therapies targeting different stages of the CoV life cycle.

摘要

人类冠状病毒（CoVs）是具有正链单链 RNA 基因组的包膜病毒。目前已报道六种人类 CoVs，包括人冠状病毒 229E（HCoV-229E）、OC43（HCoV-OC43）、NL63（HCoV-NL63）、HKU1（HCoV-HKU1）、严重急性呼吸综合征（SARS）冠状病毒（SARS-CoV）和中东呼吸综合征（MERS）冠状病毒（MERS-CoV）。它们会导致人类中、重度呼吸道和肠道感染。在本综述中，我们重点关注针对冠状病毒生命周期不同阶段的小分子抗人类冠状病毒疗法的最新研究进展。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e622/7102522/ecbc5bb999f4/gr14_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e622/7102522/9510b8b65106/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e622/7102522/abadf17ffb04/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e622/7102522/1400f9373281/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e622/7102522/e9c45d6e32fd/gr4_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e622/7102522/1a0268754a42/gr5_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e622/7102522/6f44e721e97b/gr6_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e622/7102522/89fcee48cbdb/gr7_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e622/7102522/627747b0695b/gr8_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e622/7102522/3e918a1ed09f/gr9_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e622/7102522/777d23d95a33/gr10_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e622/7102522/e824522c465a/gr11_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e622/7102522/6e6e3d62307c/gr12_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e622/7102522/241ba903af64/gr13_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e622/7102522/ecbc5bb999f4/gr14_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e622/7102522/9510b8b65106/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e622/7102522/abadf17ffb04/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e622/7102522/1400f9373281/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e622/7102522/e9c45d6e32fd/gr4_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e622/7102522/1a0268754a42/gr5_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e622/7102522/6f44e721e97b/gr6_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e622/7102522/89fcee48cbdb/gr7_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e622/7102522/627747b0695b/gr8_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e622/7102522/3e918a1ed09f/gr9_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e622/7102522/777d23d95a33/gr10_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e622/7102522/e824522c465a/gr11_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e622/7102522/6e6e3d62307c/gr12_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e622/7102522/241ba903af64/gr13_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e622/7102522/ecbc5bb999f4/gr14_lrg.jpg

相似文献

1
Recent discovery and development of inhibitors targeting coronaviruses.针对冠状病毒的抑制剂的最新发现和开发。
Drug Discov Today. 2020 Apr;25(4):668-688. doi: 10.1016/j.drudis.2020.01.015. Epub 2020 Jan 30.
2
Coronaviruses - drug discovery and therapeutic options.冠状病毒——药物研发与治疗选择
Nat Rev Drug Discov. 2016 May;15(5):327-47. doi: 10.1038/nrd.2015.37. Epub 2016 Feb 12.
3
In vitro virucidal activity of Echinaforce®, an Echinacea purpurea preparation, against coronaviruses, including common cold coronavirus 229E and SARS-CoV-2.紫锥菊制剂 Echinaforce®抗冠状病毒（包括普通感冒冠状病毒 229E 和 SARS-CoV-2）的体外病毒杀灭活性。
Virol J. 2020 Sep 9;17(1):136. doi: 10.1186/s12985-020-01401-2.
4
An overview on the seven pathogenic human coronaviruses.七种人类致病冠状病毒概述。
Rev Med Virol. 2022 Mar;32(2):e2282. doi: 10.1002/rmv.2282. Epub 2021 Aug 2.
5
Coronavirus HKU1 and other coronavirus infections in Hong Kong.香港的冠状病毒HKU1及其他冠状病毒感染
J Clin Microbiol. 2006 Jun;44(6):2063-71. doi: 10.1128/JCM.02614-05.
6
Current Strategies of Antiviral Drug Discovery for COVID-19.新型冠状病毒肺炎抗病毒药物研发的当前策略
Front Mol Biosci. 2021 May 13;8:671263. doi: 10.3389/fmolb.2021.671263. eCollection 2021.
7
HTCC as a Polymeric Inhibitor of SARS-CoV-2 and MERS-CoV.HTCC 作为 SARS-CoV-2 和 MERS-CoV 的聚合抑制剂。
J Virol. 2021 Jan 28;95(4). doi: 10.1128/JVI.01622-20.
8
Antiviral peptides against Coronaviridae family: A review.抗冠状病毒科的抗病毒肽：综述。
Peptides. 2021 May;139:170526. doi: 10.1016/j.peptides.2021.170526. Epub 2021 Mar 4.
9
High-Throughput Screening and Identification of Potent Broad-Spectrum Inhibitors of Coronaviruses.高通量筛选和鉴定冠状病毒广谱强效抑制剂。
J Virol. 2019 May 29;93(12). doi: 10.1128/JVI.00023-19. Print 2019 Jun 15.
10
Antiviral strategies against human coronaviruses.针对人类冠状病毒的抗病毒策略。
Infect Disord Drug Targets. 2007 Mar;7(1):59-66. doi: 10.2174/187152607780090757.

引用本文的文献

1
Strategy to overcome a nirmatrelvir resistance mechanism in the SARS-CoV-2 nsp5 protease.克服严重急性呼吸综合征冠状病毒2（SARS-CoV-2）非结构蛋白5（nsp5）蛋白酶中奈玛特韦耐药机制的策略。
Sci Adv. 2025 Jun 6;11(23):eadv8875. doi: 10.1126/sciadv.adv8875.
2
Unveiling the antiviral inhibitory activity of ebselen and ebsulfur derivatives on SARS-CoV-2 using machine learning-based QSAR, LB-PaCS-MD, and experimental assay.利用基于机器学习的定量构效关系（QSAR）、线性约束势全原子分子动力学（LB-PaCS-MD）和实验分析揭示依布硒啉和依布硫衍生物对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的抗病毒抑制活性。
Sci Rep. 2025 Feb 26;15(1):6956. doi: 10.1038/s41598-025-91235-1.
3

本文引用的文献

1
Remdesivir (GS-5734) protects African green monkeys from Nipah virus challenge.瑞德西韦（GS-5734）可保护非洲绿猴免受尼帕病毒攻击。
Sci Transl Med. 2019 May 29;11(494). doi: 10.1126/scitranslmed.aau9242.
2
High-Throughput Screening and Identification of Potent Broad-Spectrum Inhibitors of Coronaviruses.高通量筛选和鉴定冠状病毒广谱强效抑制剂。
J Virol. 2019 May 29;93(12). doi: 10.1128/JVI.00023-19. Print 2019 Jun 15.
3
Evaluation of a non-prime site substituent and warheads combined with a decahydroisoquinolin scaffold as a SARS 3CL protease inhibitor.
The multifaceted roles of cathepsins in immune and inflammatory responses: implications for cancer therapy, autoimmune diseases, and infectious diseases.
组织蛋白酶在免疫和炎症反应中的多方面作用：对癌症治疗、自身免疫性疾病和传染病的影响。
Biomark Res. 2024 Dec 31;12(1):165. doi: 10.1186/s40364-024-00711-9.
4
Exploring 4,7-Disubstituted Pyrimido[4,5-]pyrimidines as Antiviral and Anticancer Agents.探索4,7-二取代嘧啶并[4,5-]嘧啶作为抗病毒和抗癌药物
Molecules. 2024 Nov 25;29(23):5549. doi: 10.3390/molecules29235549.
5
Identification of novel SARS-CoV-2 3CLpro inhibitors by molecular docking, assays, molecular dynamics simulations and DFT analyses.通过分子对接、实验、分子动力学模拟和密度泛函理论分析鉴定新型严重急性呼吸综合征冠状病毒2 3C样蛋白酶抑制剂
Front Pharmacol. 2024 Oct 30;15:1494953. doi: 10.3389/fphar.2024.1494953. eCollection 2024.
6
A deep drug prediction framework for viral infectious diseases using an optimizer-based ensemble of convolutional neural network: COVID-19 as a case study.一种基于优化器的卷积神经网络集成的病毒性传染病深度药物预测框架：以COVID-19为例
Mol Divers. 2025 Jun;29(3):2473-2487. doi: 10.1007/s11030-024-11003-7. Epub 2024 Oct 9.
7
Pharmacophore-Assisted Covalent Docking Identifies a Potential Covalent Inhibitor for Drug-Resistant Genotype 3 Variants of Hepatitis C Viral NS3/4A Serine Protease.基于药效团的共价对接鉴定出一种潜在的针对丙型肝炎病毒 NS3/4A 丝氨酸蛋白酶耐药基因型 3 变异体的共价抑制剂。
Viruses. 2024 Aug 3;16(8):1250. doi: 10.3390/v16081250.
8
Inilico assessment of hesperidin on SARS-CoV-2 main protease and RNA polymerase: Molecular docking and dynamics simulation approach.橙皮苷对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）主要蛋白酶和RNA聚合酶的计算机模拟评估：分子对接和动力学模拟方法
Biochem Biophys Rep. 2024 Aug 5;39:101804. doi: 10.1016/j.bbrep.2024.101804. eCollection 2024 Sep.
9
Inhibitors of SARS-CoV-2 Main Protease (Mpro) as Anti-Coronavirus Agents.SARS-CoV-2 主蛋白酶（Mpro）抑制剂作为抗冠状病毒药物。
Biomolecules. 2024 Jul 4;14(7):797. doi: 10.3390/biom14070797.
10
Approaches Towards Better Immunosuppressive Agents.迈向更好的免疫抑制剂的方法。
Curr Top Med Chem. 2024;24(14):1230-1263. doi: 10.2174/0115680266292661240322072908.
评估非关键部位取代基和弹头与十氢异喹啉支架结合作为 SARS 3CL 蛋白酶抑制剂。
Bioorg Med Chem. 2019 Jan 15;27(2):425-435. doi: 10.1016/j.bmc.2018.12.019. Epub 2018 Dec 12.
4
Synthesis, biological evaluation and molecular modeling of a novel series of fused 1,2,3-triazoles as potential anti-coronavirus agents.新型稠合1,2,3-三唑类作为潜在抗冠状病毒药物的合成、生物学评价及分子模拟
Bioorg Med Chem Lett. 2018 Nov 15;28(21):3472-3476. doi: 10.1016/j.bmcl.2018.09.019. Epub 2018 Sep 22.
5
Post-exposure prophylaxis for Middle East respiratory syndrome in healthcare workers.医护人员中东呼吸综合征感染后的预防措施。
J Hosp Infect. 2019 Jan;101(1):42-46. doi: 10.1016/j.jhin.2018.09.005. Epub 2018 Sep 18.
6
Saracatinib Inhibits Middle East Respiratory Syndrome-Coronavirus Replication In Vitro.沙卡替尼抑制体外中东呼吸综合征冠状病毒复制。
Viruses. 2018 May 24;10(6):283. doi: 10.3390/v10060283.
7
Safe, high-throughput screening of natural compounds of MERS-CoV entry inhibitors using a pseudovirus expressing MERS-CoV spike protein.使用表达中东呼吸综合征冠状病毒刺突蛋白的假病毒对中东呼吸综合征冠状病毒进入抑制剂的天然化合物进行安全、高通量筛选。
Int J Antimicrob Agents. 2018 Nov;52(5):730-732. doi: 10.1016/j.ijantimicag.2018.05.003. Epub 2018 Oct 9.
8
Early events during human coronavirus OC43 entry to the cell.人冠状病毒 OC43 进入细胞的早期事件。
Sci Rep. 2018 May 8;8(1):7124. doi: 10.1038/s41598-018-25640-0.
9
Structure-guided design of potent and permeable inhibitors of MERS coronavirus 3CL protease that utilize a piperidine moiety as a novel design element.利用哌啶部分作为新设计元素的中东呼吸综合征冠状病毒3CL蛋白酶强效且可渗透抑制剂的结构导向设计。
Eur J Med Chem. 2018 Apr 25;150:334-346. doi: 10.1016/j.ejmech.2018.03.004. Epub 2018 Mar 6.
10
Peptide-Based Membrane Fusion Inhibitors Targeting HCoV-229E Spike Protein HR1 and HR2 Domains.基于肽的膜融合抑制剂靶向 HCoV-229E 刺突蛋白 HR1 和 HR2 结构域。
Int J Mol Sci. 2018 Feb 6;19(2):487. doi: 10.3390/ijms19020487.